A Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

This study tests a combination of two drugs — SX-682 (which blocks signals that help tumors hide from the immune system) and nivolumab (an immunotherapy drug) — as maintenance therapy for patients with advanced pancreatic cancer who have already responded to initial chemotherapy. **You may be eligible if...** - You have been diagnosed with metastatic pancreatic ductal adenocarcinoma (a type of advanced pancreatic cancer) - You have already received initial chemotherapy and have stable or responding disease - You are willing to undergo tumor biopsies and regular study visits - You are 18 or older **You may NOT be eligible if...** - Your cancer has progressed through prior treatment - You have significant organ problems that would make treatment unsafe - You are pregnant or breastfeeding - You have active autoimmune disease or are on high-dose steroids Talk to your doctor to see if this trial is right for you.